Retatrutide — Experiences & Side Effects

Triple agonist at GIP, GLP-1, and glucagon receptors. Phase 3 trials show weight loss exceeding current approved GLP-1 medications.

48 anonymous reports
CJC-1295 / Ipamorelin StackPeptides for Weight LossPeptides for RecoveryPeptides for WomenBest Peptide StacksKPV PeptidePeptides for HairStackingPeptides for LongevityPeptides for SkinPeptide Side EffectsSuccess Stories

Also known as:

retaretatrutide peptidely3437943

often mentioned with:

Page 3 of 3

Community Q&A

What is retatrutide?
Community accounts describe retatrutide as the next generation beyond tirzepatide — a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component is described as the key differentiator, adding metabolic rate elevation to the appetite suppression mechanisms of the dual agonists. Early community accounts come predominantly from early adopters who describe sourcing it through compounding channels before wider availability. Most frame it as producing faster and greater weight loss than tirzepatide at comparable dose stages.
How much weight can you lose on retatrutide?
Early community accounts describe weight loss in the range of 25–35% of starting body weight over 6–12 months, with some accounts exceeding this. The consistent framing in confessions: retatrutide outpaces tirzepatide, which already outpaces semaglutide. Side effect accounts describe a similar GI adjustment period to other GLP-1s, with nausea dominating early weeks. Account volume is still low compared to semaglutide and tirzepatide — early adopter reports rather than established community consensus.
Retatrutide vs tirzepatide — what's the difference?
Community accounts that compare both describe retatrutide as producing faster and greater weight loss, at the cost of a more pronounced adjustment period. The glucagon receptor component is described in accounts as increasing energy expenditure — the mechanism absent in tirzepatide. Accounts switching from tirzepatide to retatrutide describe continued weight loss after a tirzepatide plateau. Side effect profiles are described as broadly similar, with retatrutide's early nausea slightly more intense in comparison accounts.